Tata Consultancy Services in deal to help Congenia find drug leads for age-related diseases
Global IT company Tata Consultancy Services (TCS) is to work under a new 18-month deal with Italian bio-tech firm Congenia on a target protein involved in several age-related diseases.
Global IT company Tata Consultancy Services (TCS) is to work under a new 18-month deal with Italian bio-tech firm Congenia on a target protein involved in several age-related diseases.
Congenia, is a drug discovery company, owned by Italy's Genextra group, and active in the fields of bio-technology, biomedicine and functional genomics with particular focus on cancer pathologies related to aging and degenerative cell disorders. It hopes the new deal will provide optimised drug leads.
TCS will work on gene P66 - a target protein identified by Congenia as being involved in several age-related diseases.
It will be using modules of its own product, Bio-Suite, to work on the target protein and will screen a 'virtual fragment library' of tens of thousands of potential lead molecules to predict which of these might bind themselves to the target protein and thereby inhibit its function.
The IT company will also produce a first-cut analysis of the ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) profile of the lead molecules.
The optimised lead molecules produced will be further developed by Congenia through animal and eventually human clinical trials.